REV

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company")
announced today that the Company has strengthened its Intellectual Property
("IP") portfolio through the allowance of a key patent application for its
nutraREV(TM) food dehydration technology. The Company has also filed a new
patent application on its powderREV(TM) bulk biomaterial dehydration technology,
and received a favourable report on patentability from the international Patent
Cooperation Treaty ("PCT") Examiner on its first powderREV(TM) patent filed with
the PCT in 2010. EnWave's business model provides exclusive testing rights and
royalty-bearing licenses for products created using the Company's proprietary
Radiant Energy Vacuum ("REV") dehydration technologies. Patents are the basis on
which the Company is able to grant exclusivity of use to its multinational
partners, all of whom are contributing to the introduction of this dehydration
method to the global processing industry.


"We continue to make excellent progress through the gauntlet that is global
intellectual property protection," stated Dr. Tim Durance, Chairman and Co-CEO,
EnWave Corporation. "This is an ongoing, complex, expensive and time-consuming
process, and one that is fundamentally important to our strategy of
commercialization through partnerships with the world's largest food,
biomaterials and pharmaceutical companies."


On July 11 2011, EnWave received a "Notice of Allowance" from the Canadian
Intellectual Property Office ("CIPO") for its nutraREV(TM) equipment and method
of use patent, meaning that the patent will now be issued in Canada. The Company
expects that other jurisdictions around the world where this patent application
was filed will follow suit in granting the patent, depending on their individual
patent evaluation backlog. In January 2011, EnWave was granted a trademark in
Canada and the U.S. for its nutraDRIED(TM) brand, and the Company is now working
with several of its partners to develop co-branded nutraDRIED(TM) food products
using REV technology. EnWave's goal is for nutraDRIED(TM) to become a
recognizable standard in high-quality snack food and ingredients by consumers
all over the world.


On July 25 2011, EnWave received the International Preliminary Report on
Patentability ("IPRP") from the Patent Cooperation Treaty ("PCT") Examiner on
the Company's first patent application for powderREV(TM) bulk biomaterial
dehydration technology. The IPRP is the first official feedback that inventors
receive on a patent application, and in this case the Examiner found all 18
claims in the patent application met the triple requirements of global novelty,
inventiveness and industrial applicability. Although the PCT does not itself
grant patents, the IPRP is forwarded by the PCT to each national patent office
in which the Company will seek patent protection. A favorable IPRP is an
important step towards eventually receiving an issued patent.


Finally, on July 19 2011, EnWave filed its third patent application in the
United States on the commercial-scale design of its powderREV(TM) technology
with claims related to equipment design and methods of use. If successful, this
application will lead to patents which extend the Company's claims and control
over this technology until 2031. 


About EnWave 

EnWave Corporation is a Vancouver-based industrial technology company developing
commercial applications for its proprietary Radiant Energy Vacuum (REV)
dehydration technology. In collaboration with an expanding list of multinational
partners, including Nestle, Kellogg's, Danisco, Grupo Bimbo, and Grimmway Farms,
EnWave is introducing REV as a new dehydration standard in the food and
biological material sectors: potentially faster and cheaper than freeze drying,
with better end product quality than air drying or spray drying.


EnWave currently has six REV platforms: commercial-scale nutraREV(TM) and
MIVAP(TM) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly and at low-cost, while maintaining high levels of nutrition,
taste, texture and colour. The Company is also developing powderREV(TM) for bulk
dehydration of food cultures, probiotics and fine biochemicals such as enzymes;
quantaREV(TM) for continuous, high-volume low-temperature drying of pastes,
gels, liquids, or particulates; and bioREV(TM) and freezeREV(TM) as new methods
to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies.
More information about EnWave is available at www.enwave.net. 


EnWave Corporation 

Tim Durance, PhD, Chairman and Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures and
financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and
assumptions. There is no guarantee that the Company's REV technology can or will
improve processes in the target industry; even if the Company's REV technology
can be used as described in this document, there is no guarantee that such use
will result in orders for the Company's REV technology. All figures comparing
REV technologies to freeze drying or other dehydration technologies are provided
as examples of data obtained through the Company's own scientific and testing
programs; each product must be tested individually to determine the benefits of
using REV.

(TSXV:REV)
過去 株価チャート
から 5 2024 まで 6 2024

(TSXV:REV)
過去 株価チャート
から 6 2023 まで 6 2024